Checkpoint Inhibitor Use Surges Following FDA Approval for Gastroesophageal Cancer Treatment

A comprehensive analysis of real-world data reveals a substantial increase in the utilization of immune checkpoint inhibitors and PD-L1 testing for gastroesophageal cancer (GEC) treatment following FDA approval, according to researchers at Fox Chase Cancer Center.

The study, presented at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium in San Francisco, examined treatment patterns among 9,573 adults diagnosed with advanced GEC between 2011 and 2021.

Significant Increase in Immunotherapy Adoption

The research demonstrated a dramatic rise in checkpoint inhibitor usage, jumping from 11% before FDA approval to 37% by the second half of 2021. Simultaneously, PD-L1 testing rates increased from 68% to 77.4%, indicating broader implementation of precision medicine approaches in GEC treatment.

"GEC is a leading cause of cancer-related death, with poor survival rates due to late-stage diagnoses. Immune checkpoint inhibitors have shown promise in treating advanced GEC, especially for patients with high expression of PD-L1, a protein," explained Dr. Jasmeet Kaur, lead author and second-year fellow in the Department of Hematology/Oncology at Fox Chase.

Understanding the Mechanism

Immune checkpoint inhibitors function by blocking proteins like PD-L1, which normally prevent T cells from attacking tumor cells. By inhibiting these checkpoints, the treatment enables T cells to more effectively target and destroy cancer cells. The effectiveness of this approach has been particularly notable in patients with high PD-L1 scores, leading to significant improvements in overall survival rates.

Real-World Evidence and Implementation

The research team, comprising experts from Fox Chase Cancer Center, Temple University Hospital, and Temple Health, analyzed anonymous electronic health records from Flatiron Health's database. Their investigation examined four distinct time periods: before the presentation of new treatment data in 2020, after data presentation, following FDA approval in early 2021, and during the latter half of 2021.

Addressing Healthcare Disparities

Despite the overall positive trends, Dr. Kaur highlighted remaining challenges: "The approval of immune checkpoint inhibitors for advanced GEC led to more patients getting the right treatments and tests, but there are still gaps. Some patients, especially those from minority backgrounds, still face barriers to accessing these treatments and tests."

She emphasized the importance of developing policies and programs to ensure equitable access to cutting-edge cancer treatments across all demographic groups.